Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/pharmabcines-phase-1-clinical-trial-of-pmc-403-for-neovascular-age-related-macular-degeneration-advances-to-both-single-dose-of-4mg-and-multiple-dose-of-3mg-302187664.html
https://www.prnewswire.com/news-releases/pharmabcines-us-subsidiary-wincal-biopharm-to-present-preclinical-data-from-its-proprietary-opc-platform-targeting-ocular-diseases-at-the-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-202-302123843.html
https://www.prnewswire.com/news-releases/pharmabcine-publishes-study-in-science-advances-demonstrating-the-potential-of-pmc-403-in-preclinical-models-of-idiopathic-systemic-capillary-leak-syndrome-301996385.html
https://www.prnewswire.com/news-releases/pharmabcine-receives-safety-review-committee-approval-to-advance-to-dose-level-2-of-clinical-trial-of-pmc-403-with-neovascular-age-related-macular-degeneration-following-dose-level-1-safety-data-301982534.html
https://www.prnewswire.com/news-releases/pharmabcine-receives-ind-approval-from-the-korean-mfds-for-phase-i-clinical-trial-of-its-novel-tie2-agonistic-antibody-in-namd-301831855.html
https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-bio-international-convention-2023-301817983.html
https://www.prnewswire.com/news-releases/pharmabcine-announces-collaboration-agreement-with-msd-to-evaluate-anti-vista-antibody-pmc-309-in-combination-with-keytruda-pembrolizumab-301699915.html
https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-bio-europe-2022-301632759.html
https://www.biospectrumasia.com/news/26/20177/pharmabcine-announces-positive-results-for-its-novel-tie2-activating-antibody-in-glp-toxicology-study.html
https://www.prnewswire.com/news-releases/pharmabcine-presents-updated-preclinical-data-of-its-anti-vista-antibody-candidate-at-aacr-2022-301522480.html